OMX Ventures, a life sciences venture capital firm investing in companies that operate at the intersection of biology, big data, and engineering, has appointed Swetha Murali, PhD, as a Senior Associate based in Boston.
Working closely with the OMX Ventures partners, Murali will be involved in all aspects of the OMX Ventures investment process from deal sourcing and diligence to investment monitoring at the board level. She will also be instrumental to the team’s activities in new company creation, especially through the application of emerging technologies that can address historically overlooked or under-appreciated areas of biology.
Murali joins OMX with a particularly strong background in identifying novel emerging technologies and creating valuable drug development platforms around them.
“Swetha joins OMX with a particularly strong background in identifying novel emerging technologies and creating valuable drug development platforms around them,” says Daniel Fero, PhD, Managing Director. “We are incredibly excited to add her skills and insight to the investment team at OMX. She brings a proven aptitude for translating new scientific ideas into exciting companies, and a great ability to think strategically about company scaling and product fit. Her strengths are a perfect match with our style of working as hands-on investors and company builders with our portfolio company CEOs.”
“I am delighted to join this enthusiastic and successful team of investors,” says Murali. “I share their vision that emerging technologies have tremendous potential to shape the future of biology and society. OMX has built strong relationships with both founders and investors throughout the life sciences and tech communities. I am excited to help expand these relationships and OMX’s capabilities as we continue to invest in, grow, and create companies.”
